Uli Bialucha
Chief Scientific OfficerDr. Uli Bialucha, Ph.D., serves as Chief Scientific Officer at Xilio Therapeutics, Inc. since August 08, 2022, previously served as Senior Vice President of Research since April 2021 until August 08, 2022. Dr. Bialucha joins Xilio with a proven track record of building high-performing, multi-disciplinary teams that have delivered clinical lead molecules across a diverse array of modalities, with broad experience in oncology/immuno-oncology drug discovery and pre-clinical development. Most recently, he held the role of vice president of drug discovery at Immunitas Therapeutics, where he led the immunology and computational biology groups and was responsible for developing a single cell genomics-based discovery platform and immuno-oncology focused therapeutic pipeline. Prior to Immunitas Therapeutics, Dr. Bialucha held positions at the Novartis Institutes for Biomedical Research, where he led the oncology biotherapeutics group, directing multiple programs into clinical development, including monoclonal antibodies, T-cell engaging bispecific antibodies and antibody drug conjugates. Dr. Bialucha received his B.S. in Molecular Genetics from University of Sussex and his Ph.D. in Molecular Cell Biology from the MRC Laboratory for Molecular Cell Biology, University College London. He completed his postdoctoral training in Professor Scott Lowe’s laboratory at Cold Spring Harbor Laboratory, studying tumor suppressor gene networks using genetic mouse models of cancer.
Positions
- Company NameXilio Therapeutics, Inc.Stock CodeXLOPositionChief Scientific OfficerColleagues
- RRRene RussoPresident, CEO & Director
- SMSara M. BonsteinIndependent Chairman
- CFChristopher FrankenfieldCFO & COO
- KMKevin M. BrennanSenior Vice President of Finance & Accounting
- NMNathan McBrideChief Information Officer
- DJDaniel J. CurranIndependent Director
- JSJames S. ShannonIndependent Director
- CRCheryl Renee BlanchardIndependent Director
